MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Depression in patients with Parkinson’s disease

    M. Lisak, B. Špiljak (Zagreb, Croatia)

    Objective: The objective of this study was to correlate PD severity with depression. Background: ​​​​Depression is the most common psychiatric disorder in patients with PD. In…
  • MDS Virtual Congress 2020

    Severity of Motor Symptoms in Parkinson’s Disease in Kazakhstan (on the example of the city of Almaty)

    A. Aralbayeva, S. Kamenova, A. Kondybaeva, K. Kuzhibaeva (Almaty, Kazakhstan)

    Objective: Determine the severity of motor symptoms with Parkinson's disease using the MDS-UPDRS scale. Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by…
  • MDS Virtual Congress 2020

    Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies

    L. Elmer, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (Toledo, OH, USA)

    Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…
  • MDS Virtual Congress 2020

    Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study

    S. Isaacson, T. Clinch, E. Farbman, R. Pahwa (Boca Raton, FL, USA)

    Objective: Evaluate the effect of safinamide treatment on non-motor and motor experiences of daily living as assessed using the MDS-UPDRS (Parts I nm-EDLand II m-EDL).…
  • MDS Virtual Congress 2020

    Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease

    C. Marras, A. Naito, N. Dahodwala, A. Ramirez-Zamora, M. Rafferty, M. Neault, S. Wu, J. Beck, R. DeLeon, T. Davis (Miami, FL, USA)

    Objective: To describe the newly developed Parkinson’s Outcomes Project data sharing policy to the entire research community with a long-term goal of accelerating novel hypothesis…
  • MDS Virtual Congress 2020

    Effects of Nabilone on non-motor symptoms of Parkinson´s Disease: A randomised placebo-controlled study (The NMS-Nab Study)

    M. Peball, F. Krismer, H.G Knaus, A. Djamshidian, M. Werkmann, F. Carbone, P. Ellmerer, B. Heim, K. Marini, D. Valent, G. Goebel, H. Ulmer, H. Stockner, G.K Wenning, R. Stolz, K. Krejcy, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective: To investigate the effects of the synthetic cannabinoid nabilone for the treatment of non-motor symptoms in Parkinson´s disease (PD) in a controlled fashion. Background:…
  • MDS Virtual Congress 2020

    Resistance Training on Postural Control in Parkinson’s Disease: a Randomized Controlled Trial

    C. Souza, J. Chen, D. Francato, A. Barbosa, M. Voos, E. Barbosa, H. Chien (Sao Paulo, Brazil)

    Objective: To evaluate changes in postural control following RT using static posturography and clinical functional balance tests in Parkinson’s Disease patients Background: Muscle weakness affects…
  • MDS Virtual Congress 2020

    Clinical research of serum uric acid levels in Parkinson’s disease

    J.W Wu, T. Wang (Wuhan, China)

    Objective: To analyzed the variation of uric acid (UA) traits in different Hoehn-Yahr staging in Parkinson's disease (PD). Background: PD is a common neurodegenerative disease.…
  • MDS Virtual Congress 2020

    Patients’ Perceptions of Herbal Medicine for Parkinson’s disease: Thai Perspectives on Cannabis and Mucuna Pruriens

    T. Boonmongkol, O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To determine patients’ perceptions and knowledge of herbal medicine, including medical cannabis (MC) and Mucuna pruriens (MP), for the treatment of Parkinson’s disease (PD) Background: The use…
  • MDS Virtual Congress 2020

    Outcome Profiles in Advanced Parkinson’s Disease Patients Treated With Long-Term Levodopa-Carbidopa Intestinal Gel in a Routine Clinical Practice: Analysis From the COSMOS Study

    A. Fasano, R. García-Ramos, T. Gurevich, R. Jech, S. Femia, J. Parra, M. Simu (Toronto, ON, Canada)

    Objective: To describe the characteristics and outcomes of advanced Parkinson’s disease (PD) patients grouped by treatment duration of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa enteral suspension[CLES],…
  • « Previous Page
  • 1
  • …
  • 88
  • 89
  • 90
  • 91
  • 92
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley